Monday AM Info- 8AM EST- Hopefully To Be Immediately Followed by an Email from Greg
A Phase 1b study of gemcitabine plus PEGPH20 (PEGylated recombinant human hyaluronidase) in patients with stage IV previously untreated pancreatic cancer" will be presented by Joy Zhu M.D., Ph.D., Vice President, Oncology Clinical Development, Halozyme on Monday, September 30 in Hall 4 at 14:00 CEST. (Abstract #2598)- 6 hr diff from EST
Fezz, what is your opinion on this PHASE 1 data? Do you think this data alone makes the PPS jump or more like adds a feather to their cap? Assuming the data is good/awesome. I am excited about HALO's future but unsure about this catalyst being a major one. Your thoughts?
I Believe if it's good- Pegph20 is a great candidate for FDA Breakthrough designation and expedited review- it meets the criterion of treating a life threatening disaese and 42% ORR kills 7% for Gem alone- and beats 23% of Abraxane-Gem.